• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Healthcare·FERMENTA.BO
Share

Fermenta Biotech Ltd Stocks

₹ 401.95Last Updated 23.07.2026

Issuer Rating

3/7
Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

₹ 128.54M

₹ 401.95
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Slightly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Fermenta Biotech Ltd. primarily focuses on the creation and provision of Vitamin D3. Their extensive range of offerings includes various forms like crystalline, oil, resin in oil, cold water dispersible (CWD) preparations, and feed-grade powder. These adaptable products are utilized across multiple sectors, such as in pharmaceutical injectables, soft gel capsules, premixes, and for enhancing the nutritional value of food and beverages. The company's business activities are structured into two main divisions: the Chemicals/Bulk Drug segment, which involves the production and sale of chemicals, pharmaceutical ingredients, and enzymes; and the Property segment, dedicated to leasing out real estate. Established on May 1, 1951, by Vijay Kumar Raju Datla, the firm maintains its headquarters in Mumbai, India.

Company Valuation

Slightly undervalued
5/7

Based on key historical and expected multiples, the stock is slightly undervalued relative to its peers. In particular, the stock is underpriced on P/E, of fair value on

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

25.07.2026 01:30

"FOMO Is Turning Into a Fear of Overinvesting": Nasdaq Lost More Than 2% Over the Week

25.07.2026 00:15

The YOLO strategy has backfired: traders' favorites are on track for their worst month in four years

24.07.2026 23:35

HSBC does not expect SpaceX's stock to rise. To value the stock, it had to abandon conventional methods.

24.07.2026 23:10

Freedom recommended buying Alphabet stock after the pullback. What could hinder its growth?

24.07.2026 22:45

Key Developments in the Kazakh Market: The Stakes of the Oil War and Signals from the National Bank

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026